Related Experiment Video
Updated: May 22, 2025
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Global research trends on chronic thromboembolic pulmonary hypertension: a bibliometric analysis (January
Ye Lu1, Yicheng Yang2, Yinghui Fu3
1Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Insights
Research on chronic thromboembolic pulmonary hypertension (CTEPH) has significantly increased, with recent focus on novel therapies and diagnostic imaging. Future studies will explore underlying mechanisms and right ventricular function.
Area of Science:
- Cardiology
- Respirology
- Medical Informatics
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with significant mortality.
- Research on CTEPH has seen a substantial increase over the past two decades.
- Understanding CTEPH trends is crucial for advancing patient care and treatment strategies.
Purpose of the Study:
- To conduct a bibliometric analysis of global scientific output on CTEPH over the last 24 years.
- To identify emerging research trends and key topics in CTEPH.
- To provide insights into the evolution of CTEPH research and its future directions.
Main Methods:
- Bibliometric analysis of publications from January 1, 2000, to January 31, 2024, sourced from Web of Science Core Collection.
- Utilized Bibliometrix software for indicator analysis.
- Employed VOSviewer and CiteSpace for visualization of research trends and hotspots.
Main Results:
- A total of 2,264 publications were analyzed, showing a sharp increase in annual output.
- The United States led in publications and international cooperation, while European institutions and researchers demonstrated significant influence.
- Therapeutic focus shifted from pulmonary endarterectomy (PEA) to balloon pulmonary angioplasty (BPA) and PAH-targeted medicines, with growing interest in DECT, right ventricular function, and pulmonary endothelium.
Conclusions:
- CTEPH research has expanded significantly, establishing it as a key area in respirology and cardiology.
- Future research priorities include elucidating pathophysiological mechanisms, enhancing diagnostic accuracy, and developing innovative imaging techniques.
- Integrating current therapies and understanding right ventricular dysfunction are critical for future research endeavors.
Background:
Chronic thromboembolic pulmonary hypertension (CTEPH), a progressive disease, can lead to decompensation of the right half of the heart and death. Studies on CTEPH have increased in number over the last two decades. This study aimed to perform a bibliometric analysis of the global scientific output on CTEPH in the last 24 years to identify research trends and hot topics.
Methods:
We searched the Web of Science Core Collection (WoSCC) Science Citation Index Expanded (Science Citation Index Expanded and Social Sciences Citation Index) for literature on CTEPH published from January 1, 2000 to January 31, 2024, and recorded their information. The Bibliometrix software package was used for bibliometric indicator analysis, and VOSviewer and CiteSpace were used to visualize trends and hotspots of CTEPH research.
Results:
Overall, 2,264 publications were included in the bibliometric analysis. The number of annual publications increased drastically from 14 in 2000 to 199 in 2023. The number of publications on CTEPH has increased over the last two decades, with 24.4% (n=553) of the publications published in top academic journals. The United States ranked first in publications and had the best CTEPH-investigating institutions; it also had the highest level of international cooperation. Distinctively, 7 of the top 10 institutions and 7 of the top 10 researchers in the field were from Europe with the most influential scientists. A relatively high percentage of the publications were published in top-rank academic journals, especially in respirology and cardiology journals. Pulmonary endarterectomy (PEA) was the main therapy during the first decade, while balloon pulmonary angioplasty (BPA) and pulmonary arterial hypertension (PAH)-targeted medicine have recently gained interest. Dual-energy computed tomography (DECT), right ventricular function, and the role of pulmonary endothelium in microvasculopathy have become the focus of CTEPH research.
Conclusions:
The number of publications on CTEPH has increased over the last two decades, and CTEPH has become a significant topic in both respirology and cardiology. Our results indicate that future research in this field will continue to focus on elucidating the pathophysiological mechanisms underlying this disorder, improving diagnostic accuracy, and developing novel imaging techniques. The integration of existing therapeutic modalities and the elucidation of right ventricular dysfunction are key areas of research.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...